Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose Prednisone
Phase of Trial: Phase III
Latest Information Update: 03 Sep 2018
At a glance
- Drugs Rituximab (Primary) ; Prednisone
- Indications Nephrotic syndrome
- Focus Therapeutic Use
- 23 Aug 2018 Planned End Date changed from 20 Jan 2022 to 22 Jan 2022.
- 23 Aug 2018 Planned primary completion date changed from 2 Jan 2021 to 22 Aug 2021.
- 23 Aug 2018 Status changed from not yet recruiting to recruiting.